在晶泰科技的研发助力下，莱芒生物基于其AI+免疫代谢重编程平台，已经开发了多条研发管线。其中 代谢增强型CD19 CAR-T疗法，以低至常规CAR-T治疗剂量千分之一(1‰)的极低剂量，实现多位系统性 红斑狼疮患者完全缓解出院(100% CR)，展示了未来"门诊式"CAR-T治疗的全新可能。同时，这一疗法 已助数十位复发难治性白血病/淋巴瘤患者达到CR，并有多个实体瘤领域IIT临床正在开展或即将启动。 值得一提的是，晶泰科技与莱芒生物合作开发了META 10-AI平台，结合晶泰科技的AI算法与高通量筛 选实验，对代谢增强型 CAR-T 疗法中用到的核心代谢增强因子进行了优化设计，使其获得亲和力的数 百倍提高。目前相关结果已经申请中国专利，并应用于实体瘤靶点的代谢增强型 CAR-T 管线研发中， 大幅提高 CAR-T 细胞在实体瘤免疫微环境的抗耗竭能力。 智通财经APP获悉，晶泰科技(02228)盘中涨近5%，截至发稿，涨3.88%，报13.4港元，成交5.96亿港 元。 消息面上，近日，晶泰科技孵化企业莱芒生物在第44届摩根大通医疗健康年会(J.P. Morgan Healthcare Conference) ...

在晶泰科技的研发助力下，莱芒生物基于其AI+免疫代谢重编程平台，已经开发了多条研发管线。其中 代谢增强型CD19CAR-T疗法，以低至常规CAR-T治疗剂量千分之一(1‰)的极低剂量，实现多位系统性 红斑狼疮患者完全缓解出院(100%CR)，展示了未来"门诊式"CAR-T治疗的全新可能。同时，这一疗法 已助数十位复发难治性白血病/淋巴瘤患者达到CR，并有多个实体瘤领域IIT临床正在开展或即将启动。 值得一提的是，晶泰科技与莱芒生物合作开发了META10-AI平台，结合晶泰科技的AI算法与高通量筛 选实验，对代谢增强型CAR-T疗法中用到的核心代谢增强因子进行了优化设计，使其获得亲和力的数百 倍提高。目前相关结果已经申请中国专利，并应用于实体瘤靶点的代谢增强型CAR-T管线研发中，大幅 提高CAR-T细胞在实体瘤免疫微环境的抗耗竭能力。 晶泰科技(02228)盘中涨近5%，截至发稿，涨3.88%，报13.4港元，成交5.96亿港元。 消息面上，近日，晶泰科技孵化企业莱芒生物在第44届摩根大通医疗健康年会(J.P.Morgan Healthcare Conference)发表演讲，并向全球投资者展示了其极低剂量C ...

近日，晶泰科技(02228)孵化企业莱芒生物在第44届摩根大通医疗健康年会(J.P.Morgan Healthcare Conference)发表演讲，并向全球投资者展示了其极低剂量CAR-T疗法的研究者发起临床(IIT)最新成果。 在晶泰科技的研发助力下，莱芒生物基于其AI+免疫代谢重编程平台，已经开发了多条研发管线。其中 代谢增强型CD19CAR-T疗法，以低至常规CAR-T治疗剂量千分之一(1‰)的极低剂量，实现多位系统性 红斑狼疮患者完全缓解出院(100%CR)，展示了未来"门诊式"CAR-T治疗的全新可能。同时，这一疗法 已助数十位复发难治性白血病/淋巴瘤患者达到CR，并有多个实体瘤领域IIT临床正在开展或即将启动。 这一系列进展再次印证了晶泰科技研发平台在赋能颠覆性技术、加速临床转化方面的卓越能力。 在晶泰科技的投资孵化与研发赋能下，莱芒生物聚焦创新肿瘤免疫治疗药物管线的研发，开发并持续升 级其独有的META10代谢重编程技术平台。两家公司还合作开发了META10-AI平台，结合晶泰科技的AI 算法与高通量筛选实验，对代谢增强型CAR-T疗法中用到的核心代谢增强因子进行了优化设计，使其获 得亲和力 ...

智通财经APP获悉，近日，晶泰科技(02228)孵化企业莱芒生物在第 44 届摩根大通医疗健康年会(J.P. Morgan Healthcare Conference)发表演讲，并向全球投资者展示了其极低剂量 CAR-T 疗法的研究者发起 临床(IIT)最新成果。在晶泰科技的研发助力下，莱芒生物基于其 AI+免疫代谢重编程平台，已经开发了 多条研发管线。其中代谢增强型 CD19 CAR-T 疗法，以低至常规 CAR-T 治疗剂量千分之一(1‰)的极低 剂量，实现多位系统性红斑狼疮患者完全缓解出院(100% CR)，展示了未来"门诊式" CAR-T 治疗的全 新可能。同时，这一疗法已助数十位复发难治性白血病/淋巴瘤患者达到 CR，并有多个实体瘤领域 IIT 临床正在开展或即将启动。这一系列进展再次印证了晶泰科技研发平台在赋能颠覆性技术、加速临床转 化方面的卓越能力。 在晶泰科技的投资孵化与研发赋能下，莱芒生物聚焦创新肿瘤免疫治疗药物管线的研发，开发并持续升 级其独有的 META 10 代谢重编程技术平台。两家公司还合作开发了 META 10-AI 平台，结合晶泰科技 的AI算法与高通量筛选实验，对代谢增强型 C ...

Summary of Key Points from the Conference Call Company Overview - **Company Name**: Jin Ai Holdings - **Industry**: AI-driven pharmaceutical discovery and automation solutions - **Core Business**: 85% drug discovery, 15% smart automation solutions [2][3] Core Insights and Arguments - **Technology Utilization**: Jin Ai Holdings leverages quantum physics and AI to enhance drug discovery, significantly improving the efficiency of AI model training and reducing the drug development cycle to 2 years [2][3] - **Revenue Model**: The company generates revenue through R&D service fees, milestone payments, and sales sharing, focusing on high-margin services [2][3] - **Partnerships**: In 2025, Jin Ai Holdings signed a total of $6.25 billion in orders with Eli Lilly, including $250 million for small molecules and $6 billion for large molecules, and entered into a collaboration with Gan Li Pharmaceutical in the peptide metabolism field [4] - **Non-Pharmaceutical Ventures**: The company is expanding into non-drug areas, collaborating with Sinopec, Peking University, and JW Pharmaceutical, and has formed a joint venture with Jinko Solar to develop perovskite tandem solar cells, expected to achieve mass production by 2028 [2][5][8] Important Developments - **Hair Growth Product**: Jin Ai Holdings launched a self-developed hair growth product, which received FDA approval and is expected to gain domestic raw material registration by 2026. The product is priced at 389 RMB and has shown a high efficacy rate in clinical trials [6][7] - **Market Potential**: Approximately 2.5 billion people globally face hair loss issues, indicating a significant market opportunity for the hair growth product [6] - **Automation Laboratory**: The company’s automated laboratory is set to enhance data quality and efficiency, with plans to implement it by the end of 2024 [3][12] Competitive Advantages - **Data Generation**: Jin Ai Holdings' quantum physics-based AI model can generate large-scale data for training, allowing breakthroughs in data-scarce areas, outperforming 90% of commercial software in the market [3][11] - **Flexibility in Business Model**: Unlike traditional pharmaceutical companies, Jin Ai Holdings does not bear the risks of clinical development, allowing for a more flexible and efficient revenue growth strategy [10][11] - **Collaboration with Major Firms**: The company maintains strong partnerships with major pharmaceutical firms like Eli Lilly and technology companies like NVIDIA, focusing on collaborative projects rather than direct competition [14][15] Future Outlook - **R&D Efficiency**: AI in drug discovery is expected to enhance efficiency and reduce costs by generating millions of small molecules and significantly speeding up the testing process through automation [16][17] - **Perovskite Solar Cells**: The joint venture with Jinko Solar aims to address the challenges of perovskite solar cells, with a focus on improving stability and performance for potential space applications [8] This summary encapsulates the key points discussed in the conference call, highlighting Jin Ai Holdings' innovative approach, strategic partnerships, and future growth potential in both pharmaceutical and non-pharmaceutical sectors.

香港联交所最新资料显示，1月12日，摩根大通增持晶泰控股(02228)2996.4263万股，每股作价12.5925 港元，总金额约为3.77亿港元。增持后最新持股数目约为4.01亿股，最新持股比例为9.31%。 ...

智通财经APP获悉，香港联交所最新资料显示，1月12日，摩根大通增持晶泰控股(02228)2996.4263万 股，每股作价12.5925港元，总金额约为3.77亿港元。增持后最新持股数目约为4.01亿股，最新持股比例 为9.31%。 ...

Core Insights - The top three companies with the highest short positions as of January 9 are Vanke Enterprises (02202), Dongfang Electric (01072), and COSCO Shipping Holdings (01919), with short ratios of 18.74%, 17.39%, and 16.49% respectively [1][2] - The companies with the largest absolute increase in short positions are Goldwind Technology (02208), Zhaoyan New Drug (06127), and Jingtai Holdings (02228), with increases of 6.84%, 2.14%, and 1.85% respectively [1][2] - The companies with the largest absolute decrease in short positions are COSCO Shipping Energy (01138), Sanhua Intelligent Control (02050), and Huahong Semiconductor (01347), with decreases of -1.77%, -0.80%, and -0.71% respectively [1][3] Top 10 Short Positions - Vanke Enterprises (02202) has a short position of 413 million shares, representing a short ratio of 18.74% [2] - Dongfang Electric (01072) has a short position of 70.93 million shares, with a short ratio of 17.39% [2] - COSCO Shipping Holdings (01919) has a short position of 475 million shares, with a short ratio of 16.49% [2] - Other notable companies in the top 10 include Heng Rui Medicine (01276) at 15.19% and Ping An Insurance (02318) at 14.74% [2] Largest Increases in Short Positions - Goldwind Technology (02208) saw its short ratio increase from 4.35% to 11.18%, an increase of 6.84% [2] - Zhaoyan New Drug (06127) increased from 6.65% to 8.79%, an increase of 2.14% [2] - Jingtai Holdings (02228) increased from 3.34% to 5.19%, an increase of 1.85% [2] Largest Decreases in Short Positions - COSCO Shipping Energy (01138) decreased from 7.11% to 5.34%, a decrease of -1.77% [3] - Sanhua Intelligent Control (02050) decreased from 6.52% to 5.72%, a decrease of -0.80% [3] - Huahong Semiconductor (01347) decreased from 4.85% to 4.13%, a decrease of -0.71% [3]

Core Insights - On January 15, 2026, Alibaba-W (09988), Tencent Holdings (00700), and SMIC (00981) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 84.25 billion, 33.70 billion, and 28.12 billion respectively [1][2] - In the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), Tencent Holdings (00700), and Xiaomi Group-W (01810) also ranked as the top three, with trading amounts of 44.51 billion, 17.26 billion, and 14.74 billion respectively [1][2] Southbound Stock Connect Trading Activity - The top three active companies in the Southbound Stock Connect by trading amount were: - Alibaba-W (09988): 84.25 billion with a net buy of +17.90 billion - Tencent Holdings (00700): 33.70 billion with a net buy of +6.63 billion - SMIC (00981): 28.12 billion with a net buy of +3.57 billion [2] - Other notable companies included: - China Mobile (00941): 17.74 billion with a net sell of -7.91 billion - China National Offshore Oil (00883): 14.80 billion with a net sell of -6.66 billion [2] Shenzhen-Hong Kong Stock Connect Trading Activity - The top three active companies in the Shenzhen-Hong Kong Stock Connect by trading amount were: - Alibaba-W (09988): 44.51 billion with a net buy of +1.86 billion - Tencent Holdings (00700): 17.26 billion with a net sell of -2042.91 million - Xiaomi Group-W (01810): 14.74 billion with a net sell of -4.91 billion [2] - Other notable companies included: - China National Offshore Oil (00883): 11.74 billion with a net buy of +3.00 billion - Meituan-W (03690): 7.07 billion with a net buy of +1.28 billion [2]

海外层面，北美巨头26年开年密集推进AI+医疗实质性产品和功能落地 1月8日，OpenAI重磅推出了ChatGPT Health，为客户提供健康咨询服务，每周超2.3亿人咨询健康问 题；1月12日，英伟达与礼来宣布将在五年内斥资10亿美元在旧金山湾区建立一个新的联合研究实验 室，以加速AI药物研发进程；1月12日，Anthropic宣布推出医疗保健和生命科学服务，使其Claude人工 智能平台的用户能够共享对其健康记录的访问权限，以便更好地了解用户的医疗信息；1月14日， OpenAI宣布1亿美元收购仅4名员工的线上医疗数据整合商Torch。 智通财经APP获悉，中邮证券发布研报称，全球药物研发外包服务市场规模将由2023年的1512亿美元进 一步增至2030年的3632亿美元，CAGR为13.3%。AI已成为新药物发现的"加速引擎"，通过预测结合 能、溶解性、毒性等关键参数，AI可以在虚拟空间中高速筛选、优化甚至从头设计出具有潜力的候选 分子或新材料，有望缩短药物发现时间。展望2026年，以晶泰、TEMPUS为代表的AI+制药赛道领军均 有望实现EBITDA首次转正，产业即将迎来估值重构期。 中邮证券主要观 ...